8-K current report · filed Aug 4, 2026

Pacira BioSciences, Inc. (PCRX) 8-K Current Report: August 4, 2026

Item EX-99.1Item 2.02PCRX overview

Short answer

Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Pacira BioSciences announced second-quarter 2026 financial results for the period ended June 30, 2026.

Pacira BioSciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Pacira BioSciences announced second-quarter 2026 financial results for the period ended June 30, 2026
  • Results press release issued August 4, 2026, with full financial details in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $192.4M, up 6%, led by EXPAREL sales of $147.8M, up 3% despite discounting pressure
  • GAAP net income $4.7M versus $4.8M loss, while adjusted EBITDA declined to $48.7M from $54.3M
  • iovera° divestiture closed July 31 for $73.6M cash, with potential proceeds up to $140M through 2031
  • 2026 revenue guidance reduced to $735M-$760M, reflecting iovera° removal after July 31
  • UnitedHealthcare separate EXPAREL reimbursement expands access across outpatient settings covering approximately 40M lives

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Pacira BioSciences, Inc. 8-K filings

Get the next PCRX 8-K as it lands

Follow PCRX for push alerts, or ask the research agent what this filing means.